Pre-made Lilotomab biosimilar ( Whole mAb ADC, anti-CD37 therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-313
Anti-CD37 therapeutic antibody (Pre-made Lilotomab biosimilar,Whole mAb ADC) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Lilotomab (formerly tetulomab, HH1) is a murine monoclonal antibody against CD37, a glycoprotein which is expressed on the surface of mature human B cells. It was generated at the Norwegian Radium Hospital.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-CD37 therapeutic antibody (Pre-made Lilotomab biosimilar,Whole mAb ADC)|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Active||Follicular lymphoma;Non-Hodgkin's lymphoma;Diffuse large B cell lymphoma|